by Richard Daverman, PhD
July 10, 2012 -- Yunnan Walvax Biotechnology, a vaccine company, obtained a 51% stake in Shanghai Fengmao Biotechnology Co. Walvax will establish subsidiaries of Fengmao to produce five monoclonal antibodies and a sustained-release version of the anemia treatment EPO. Walvax will invest 102 million RMB ($16 million), in a combination of cash and technology, to obtain control of Fengmao. More details....
Stock Symbol: (SHE: 300142)
